文献速递姑息放疗与转移瘤

立体定向体部放疗治疗寡进展:联合或不联合全身治疗转换

Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-02-23

研究纳入2014年1月至2019年12月期间在本机构接受立体定向体部放疗(SBRT)治疗的全部寡进展病灶的实体瘤患者135例,比较寡进展后继续或转换全身治疗患者的结局。中位随访27.2个月,转换组与继续组的中位总生存(32.1 vs 38.2个月,p=0.47)和无进展生存(4.3 vs 3.4个月,p=0.6)相当,至下一线全身治疗间隔两组亦相当(p=0.6)。

要点

  • 寡进展后继续与转换全身治疗的患者,中位总生存和无进展生存均无显著差异。
  • ECOG体能状态评分2分及寡进展后立即开始新全身治疗与至下一线全身治疗生存较差相关。
  • 原发寡转移状态较诱导寡转移状态与至下一线全身治疗生存较好相关。

核心结论

  • SBRT治疗寡进展后继续或转换全身治疗的患者肿瘤学结局相当,可能提示在部分病例中可安全延迟后续治疗线。

研究设计与样本

  • 单机构研究,纳入2014年1月至2019年12月期间接受SBRT治疗全部寡进展病灶的实体瘤患者135例,其中最常见原发肿瘤为肺癌(n=46,34.1%)。
  • 寡进展定义为在积极全身治疗下有限数量转移灶的癌症进展;纳入标准为出现至多5个颅外进展转移灶并接受SBRT治疗所有病灶。
  • 采用Kaplan-Meier法分析总生存(OS)和无进展生存(PFS),采用累积发生率函数确定至下一线全身治疗间隔,采用多因素Cox回归模型分析基线和进展后变量对OS、PFS及SBRT后至下一线全身治疗生存的影响。

主要发现

  • 135例患者中,96例在寡进展后继续当前全身治疗线,39例转换全身治疗,其中28例(71.8%)暂停或中断,11例(28.2%)立即开始另一全身治疗。
  • 中位随访27.2个月,转换组与继续组的中位OS分别为32.1个月 vs 38.2个月(p=0.47),中位PFS分别为4.3个月 vs 3.4个月(p=0.6),均无显著差异。
  • 至下一线全身治疗间隔在两组间相当(p=0.6)。
  • ECOG体能状态评分2分和寡进展后立即开始新全身治疗与至下一线全身治疗生存较差相关。
  • 原发寡转移状态较诱导寡转移状态与至下一线全身治疗生存较好相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oligoprogression is defined as cancer progression of a limited number of metastases under active systemic therapy. The role of metastasis-directed therapy, using stereotactic body radiotherapy (SBRT), is controversial as is the continuation versus switch of systemic therapy. We report outcomes of oligoprogressive patients after SBRT, and compare those patients that continued or switched their current line of systemic therapy. MATERIAL/METHODS: We included patients who developed up to 5 progressive extracranial metastases under systemic therapy for any solid organ malignancy and were treated with SBRT to all lesions at our institution between 01/2014 and 12/2019. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method, and the interval to the next systemic therapy line determined using cumulative incidence functions. Multivariable Cox regression models were used to analyze the influence of baseline and post-progression variables on OS, PFS and survival with the next systemic therapy after SBRT. RESULTS: Among 135 patients with oligoprogressive disease of which the most common primary tumor was lung cancer (n = 46, 34.1 %), 96 continued their current line of systemic therapy after oligoprogression. Among 39 who switched systemic therapy, 28 (71.8 %) paused or discontinued, while 11 (28.2 %) immediately started another systemic treatment. After a median follow-up of 27.2 months, patients that switched and those who continued systemic therapy after oligoprogression had comparable median OS (32.1 vs. 38.2 months, p = 0.47) and PFS (4.3 vs. 3.4 months, p = 0.6). The intervals to the next systemic therapy line were comparable between both cohorts (p = 0.6). An ECOG performance status of 2 and immediately starting a new systemic therapy after oligoprogression were associated with a poorer survival without next systemic therapy, while the de-novo OMD state was associated with better survival without next systemic therapy compared to the induced state. CONCLUSION: Oncological outcomes of patients that continued or switched systemic therapy after SBRT for oligoprogression were comparable, potentially indicating that further lines of treatment may be safely delayed in selected cases.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Willmann J, Vlaskou Badra E, Adilovic S, et al. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy. Clin Transl Radiat Oncol. 2024. PMID: 38433950. doi:10.1016/j.ctro.2024.100748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。